AEM vs LOMA

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

LOMA presents a stark contrast between deterministic value and market expectations. With a Piotroski F-Score of 4/9, the company's financial health is stable but lacks strength, while the current price of $10.86 trades at a massive premium to both the Graham Number ($4.76) and the Intrinsic Value ($1.05). While trailing earnings have collapsed by 82.20%, a significantly lower forward P/E of 12.86 and strong Q/Q revenue growth (26.93%) suggest the market is pricing in a cyclical recovery. The low debt-to-equity ratio provides a safety buffer, but the low quick ratio indicates liquidity is heavily tied up in inventory.